It is known that PI3K pharmacological blockade significantly reduces the proliferation rate in culture, suggesting that inhibition of PI3K might prove beneficial in experimental therapies [26] especially in IPMN patients with overexpression of PIK3CA. This evidence concerns the gene PIK3CA and pancreatic intraductal papillary-mucinous neoplasm.